Holen Sie sich die Stockscreener-App
4.40
1.79%
-0.08
Handel nachbörslich:
4.40
Schlusskurs vom Vortag:
$4.48
Offen:
$4.48
24-Stunden-Volumen:
2.22M
Relative Volume:
1.08
Marktkapitalisierung:
$649.03M
Einnahmen:
$185.74M
Nettoeinkommen (Verlust:
$-230.76M
KGV:
-4.857
EPS:
-0.9059
Netto-Cashflow:
$-70.72M
1W Leistung:
+6.02%
1M Leistung:
+19.24%
6M Leistung:
+17.33%
1J Leistung:
+91.72%
1-Tages-Spanne:
$4.3413
$4.52
1-Wochen-Bereich:
$4.00
$4.52
52-Wochen-Spanne:
$1.99
$4.995
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
4.40 | 660.83M | 185.74M | -230.76M | -70.72M | -0.9059 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79 - Stock Titan
Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares - Stock Titan
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference - Business Wire
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI) - Seeking Alpha
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai LifeSciences Holdings, Inc. Sued for Securities Law Viola - The National Law Review
Maravai LifeSciences Holdings (MRVI) price target increased by 23.91% to 5.81 - MSN
12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI) - Stock Titan
Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook - Sahm
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance - Yahoo Finance
Maravai LifeSciences stock (US56600D1072): Q1 turnaround and CleanCap momentum draw fresh investor a - AD HOC NEWS
Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI) - Stock Titan
Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G - Stock Titan
TradingKey - TradingKey
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Maravai Lifesciences Signals Turnaround in Earnings Call - TipRanks
MRVI (Maravai) EPS crushes estimates by 121%, but shares fall 3% despite profit surprise.Community Chart Signals - Newser
Maravai (MRVI) Q1 2026 Earnings Transcript - AOL.com
All you need to know about Maravai LifeSciences (MRVI) rating upgrade to buy - MSN
Maravai LifeSciences Holdings, Inc. Q1 2026 Financial Results, Risks, and Forward-Looking Statements - Minichart
Maravai LifeSciences Holdings, Inc. (MRVI) tops Q1 earnings and revenue estimates - MSN
Maravai Q1 2026 slides: 41% revenue surge drives profitability return By Investing.com - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) EPS Loss Deepens Narrative On Persistent Profitability Concerns - simplywall.st
Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt - Stock Titan
Maravai LifeSciences Is Maintained at Overweight by Wells Fargo - Moomoo
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Announces Target Price $5 - Moomoo
MRVI Maintained by Wells Fargo -- Price Target Raised to $5.50 - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday SessionAIM ImmunoTech (AMEX:AIM), Akanda (NASDAQ:AKA - Benzinga
Wells Fargo & Company Forecasts Strong Price Appreciation for Maravai LifeSciences (NASDAQ:MRVI) Stock - MarketBeat
Deutsche Bank Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Q1 Earnings Call Highlights - Barchart
Maravai LifeSciences Reports First Quarter 2026 Financial Results - BioSpace
Maravai Q1 2026 slides: 41% revenue surge drives profitability return - Investing.com
Earnings call transcript: Maravai Lifesciences Q1 2026 beats forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q1 2026 beats forecasts, stock rises - Investing.com Australia
Maravai LifeSciences Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-05-07 - Seeking Alpha
Maravai LifeSciences Holdings Q1 2026 earnings preview - MSN
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Maravai LifeSciences Surges on Strong Q1, Raises Full-Year Outlook - BriefGlance
Maravai LifeSciences (NASDAQ:MRVI) Surges After Crushing Q1 Estimates and Raising Full-Year Guidance - ChartMill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Q1 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript - GuruFocus
Maravai (NASDAQ: MRVI) lifts 2026 outlook after 41% Q1 revenue surge - Stock Titan
How many employees work at Maravai Lifesciences? - Revelio Labs
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy - Yahoo Finance
Maravai (MRVI) Stock: Price Pattern Formation | Maravai posts 44.7% EPS beat on narrower Q4 lossBest Pick - Newser
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):